Fred Martin
Disciplined Growth Investors
Fred Martin CLOVIS ONCOLOGY INC stake
total: 241
Disciplined Growth Investors CLVSQ trades
- Total transactions:
- 2
- New positions:
- 1
- Sold out:
- 1
- Held since:
- 2020 Q4
- Held for:
- 1 quarter
- Latest activity:
- 2021 Q1
According to 2026 Q2 report, Fred Martin doesn't hold any CLOVIS ONCOLOGY INC (CLVSQ) shares. To date, the estimated cost basis is nearly $4.79 for "buy" trades and estimated average "sell" price is $4.79. Disciplined Growth Investors first purchased CLVSQ in 2020 Q4, initially acquiring 14,000 shares. Since the initial investment in CLOVIS ONCOLOGY INC (CLVSQ), Disciplined Growth Investors has made 1 more transaction.
When did Fred Martin sell CLOVIS ONCOLOGY INC (CLVSQ)?
Fred Martin sold off the entire CLOVIS ONCOLOGY INC (CLVSQ) position in 2021 Q1.
When did Fred Martin buy CLOVIS ONCOLOGY INC (CLVSQ)?
Fred Martin first invested in CLOVIS ONCOLOGY INC (CLVSQ) in 2020 Q4 at the reported quarter-end price of $4.79 per share.
What's the cost basis of Disciplined Growth Investors's CLVSQ stake?
The estimated cost basis for CLOVIS ONCOLOGY INC (CLVSQ) stake is around $4.79 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $4.79
- Weighted AVG sell price:
- $4.79
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.